Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.

< BACK TO ARCHIVE


Papers: 7 Nov 2020 - 13 Nov 2020


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2020 Nov 09


Headache


http://www.ncbi.nlm.nih.gov/pubmed/33165938?dopt=Abstract

Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.

Authors

Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.
Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S
Headache. 2020 Nov 09.
PMID: 33165938.

Abstract

To determine the onset of preventive efficacy with eptinezumab in patients with migraine.
Read This Paper